Evolus (NASDAQ:EOLS) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of Evolus (NASDAQ:EOLS) from a buy rating to a hold rating in a research report sent to investors on Sunday.

A number of other research analysts have also recently weighed in on the stock. Stifel Nicolaus dropped their target price on shares of Evolus from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Tuesday, January 13th. Mizuho set a $15.00 price target on shares of Evolus in a research note on Wednesday, February 4th. HC Wainwright lowered their price target on shares of Evolus from $20.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Needham & Company LLC reiterated a “hold” rating on shares of Evolus in a research note on Wednesday, December 24th. Finally, BTIG Research reissued a “buy” rating and set a $13.00 price objective on shares of Evolus in a report on Wednesday, March 4th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Evolus currently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Evolus Trading Down 2.6%

NASDAQ EOLS opened at $4.91 on Friday. The business has a fifty day simple moving average of $4.85 and a 200 day simple moving average of $6.09. Evolus has a 12 month low of $4.09 and a 12 month high of $13.66. The firm has a market capitalization of $319.44 million, a P/E ratio of -6.06 and a beta of 1.02.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported $0.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The business had revenue of $90.30 million for the quarter, compared to analysts’ expectations of $89.58 million. As a group, sell-side analysts predict that Evolus will post -0.61 EPS for the current fiscal year.

Insider Transactions at Evolus

In other Evolus news, insider David Moatazedi sold 10,539 shares of the business’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $7.15, for a total value of $75,353.85. Following the sale, the insider owned 354,388 shares in the company, valued at $2,533,874.20. The trade was a 2.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Nantahala Capital Management LLC lifted its position in shares of Evolus by 1.6% in the fourth quarter. Nantahala Capital Management LLC now owns 5,820,649 shares of the company’s stock worth $38,707,000 after buying an additional 93,792 shares in the last quarter. Caligan Partners LP grew its holdings in Evolus by 23.8% during the 3rd quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock valued at $25,413,000 after buying an additional 796,973 shares in the last quarter. Vanguard Group Inc. grew its holdings in Evolus by 3.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,428,943 shares of the company’s stock valued at $21,054,000 after buying an additional 110,693 shares in the last quarter. Braidwell LP bought a new stake in Evolus in the 4th quarter worth approximately $20,650,000. Finally, Frazier Life Sciences Management L.P. bought a new stake in Evolus in the 2nd quarter worth approximately $22,431,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.